Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Is the FDA Delay Actually Good News for Biogen's Alzheimer's Drug?

TheMotleyFool

0 0

Is the FDA Delay Actually Good News for Biogen's Alzheimer's Drug?

The Food and Drug Administration (FDA) recently extended its timeframe to approve or reject Biogen (NASDAQ: BIIB) and Eisai's (OTC: ESALY) Alzheimer's disease drug aducanumab by three months to June 7, 2021. In this video from Motley Fool Live, recorded on Feb. 1, Fool.com contributors Brian Orelli and Keith Speights discuss how the delay could actually be good news for the companies.

Source Fool.com

Like: 0

BIIB

Share